Furthermore, Astragalus polysaccharide, when used in combination with targeted therapies such as apatinib, inhibits the protein kinase b/extracellular signal-regulated kinase signaling pathway, reduces the expression of matrix metalloproteinase-9, suppresses the invasion and metastasis of GC cells, and promotes the conversion of TAMs from the M2 to M1, thereby activating the anti-tumor immune response. This evidence concerns the gene AKT1 and neoplasm.